Elizabeth Baumann
Acute Care · Birmingham, ALNPI 1356961817
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 356 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Mallinckrodt Hospital Products Inc.$1K
- Grifols USA, LLC$564
- Boehringer Ingelheim$509
- Takeda Pharmaceuticals U.S.A., Inc.$455
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,73299%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 70 | $1,406 |
| AstraZeneca | 59 | $1,135 |
| Mallinckrodt Hospital Products Inc. | 38 | $1,058 |
| Grifols USA, LLC | 25 | $564 |
| Boehringer Ingelheim | 24 | $509 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $455 |
| Regeneron Healthcare Solutions, Inc. | 15 | $332 |
| Baxter Healthcare | 9 | $314 |
| Mylan Specialty L.p. | 14 | $314 |
| Merck | 14 | $282 |
| Philips North America LLC | 14 | $271 |
| Sanofi | 11 | $241 |
| ANI Pharmaceuticals, Inc. | 5 | $109 |
| United Therapeutics Corporation | 4 | $98 |
| Amgen | 5 | $96 |
| Inogen, Inc. | 5 | $94 |
| Vifor Pharma, Inc. | 3 | $90 |
| Harmony Biosciences LLC | 4 | $88 |
| CSL Behring | 3 | $72 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| La Jolla Pharmaceutical Company | 2 | $35 |
| Pulmonx Corporation | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Edwards Lifesciences | 1 | $26 |
| Verona Pharma, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Pfizer | 1 | $20 |
| Shionogi Inc | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$7,832 in reported general payments places this provider in the 90th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $54,360 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $30,666 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $17,982 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $10,781 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 140 | $4,095 |
| Arnuity ElliptaFluticasone Furoate | 21 | $3,365 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,640 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $1,502 |
| Montelukast Sodium | 96 | $1,013 |
| Ventolin HfaAlbuterol Sulfate | 12 | $665 |
| Prednisone | 14 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,406 | $86,488145 claims |
| AstraZenecaBreztri Aerosphere | $1,135 | $30,66645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 711 acute care providers in Alabama.
Other acute care in Birmingham
- Coretta CollinsBirmingham$77K
- Cameron StephensonBirmingham$13K
- Jonathan McCraryBirmingham$13K
- Michelle PriceBirmingham$13K
- Melissa FrenchBirmingham$13K
- Jaime CannonBirmingham$12K
- Kaci WeaverBirmingham$11K
- Alexandra GlennBirmingham$11K
- Bridget CrainBirmingham$10K
- Rachel CookBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.